(Reuters) - U.S. health regulators have approved a new breast cancer drug from Roche Holding AG that the company hopes will become the standard treatment for women with an aggressive, incurable form of cancer. Roche unit Genentech announced Friday that the Food and Drug Administration approved the injectable drug Perjeta for women with a type of breast cancer known as HER-2 positive, which makes up about a quarter of all breast cancers and has no cure. Analysts predict the medicine could be another blockbuster cancer drug for the Swiss company.
By Anna Yukhananov
Fri Jun 8, 2012 9:23pm EDT
Click here to read the whole story
Return to GoPath by clicking back arrow on the webpage